Global burden of maternal and congenital syphilis and associated adverse birth outcomes-Estimates for 2016 and progress since 2012.
Cost of Illness
Female
Global Health
/ statistics & numerical data
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Pregnancy Outcome
/ epidemiology
Prevalence
Stillbirth
/ epidemiology
Syphilis
/ complications
Syphilis, Congenital
/ epidemiology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
09
2018
accepted:
26
10
2018
entrez:
28
2
2019
pubmed:
28
2
2019
medline:
13
11
2019
Statut:
epublish
Résumé
In 2007 the World Health Organization (WHO) launched the global initiative to eliminate mother-to-child transmission of syphilis (congenital syphilis, or CS). To assess progress towards the goal of <50 CS cases per 100,000 live births, we generated regional and global estimates of maternal and congenital syphilis for 2016 and updated the 2012 estimates. Maternal syphilis estimates were generated using the Spectrum-STI model, fitted to sentinel surveys and routine testing of pregnant women during antenatal care (ANC) and other representative population data. Global and regional estimates of CS used the same approach as previous WHO estimates. The estimated global maternal syphilis prevalence in 2016 was 0.69% (95% confidence interval: 0.57-0.81%) resulting in a global CS rate of 473 (385-561) per 100,000 live births and 661,000 (538,000-784,000) total CS cases, including 355,000 (290,000-419,000) adverse birth outcomes (ABO) and 306,000 (249,000-363,000) non-clinical CS cases (infants without clinical signs born to un-treated mothers). The ABOs included 143,000 early fetal deaths and stillbirths, 61,000 neonatal deaths, 41,000 preterm or low-birth weight births, and 109,000 infants with clinical CS. Of these ABOs- 203,000 (57%) occurred in pregnant women attending ANC but not screened for syphilis; 74,000 (21%) in mothers not enrolled in ANC, 55,000 (16%) in mothers screened but not treated, and 23,000 (6%) in mothers enrolled, screened and treated. The revised 2012 estimates were 0.70% (95% CI: 0.63-0.77%) maternal prevalence, and 748,000 CS cases (539 per 100,000 live births) including 397,000 (361,000-432,000) ABOs. The estimated decrease in CS case rates between 2012 and 2016 reflected increased access to ANC and to syphilis screening and treatment. Congenital syphilis decreased worldwide between 2012 and 2016, although maternal prevalence was stable. Achieving global CS elimination, however, will require improving access to early syphilis screening and treatment in ANC, clinically monitoring all women diagnosed with syphilis and their infants, improving partner management, and reducing syphilis prevalence in the general population by expanding testing, treatment and partner referral beyond ANC.
Sections du résumé
BACKGROUND
In 2007 the World Health Organization (WHO) launched the global initiative to eliminate mother-to-child transmission of syphilis (congenital syphilis, or CS). To assess progress towards the goal of <50 CS cases per 100,000 live births, we generated regional and global estimates of maternal and congenital syphilis for 2016 and updated the 2012 estimates.
METHODS
Maternal syphilis estimates were generated using the Spectrum-STI model, fitted to sentinel surveys and routine testing of pregnant women during antenatal care (ANC) and other representative population data. Global and regional estimates of CS used the same approach as previous WHO estimates.
RESULTS
The estimated global maternal syphilis prevalence in 2016 was 0.69% (95% confidence interval: 0.57-0.81%) resulting in a global CS rate of 473 (385-561) per 100,000 live births and 661,000 (538,000-784,000) total CS cases, including 355,000 (290,000-419,000) adverse birth outcomes (ABO) and 306,000 (249,000-363,000) non-clinical CS cases (infants without clinical signs born to un-treated mothers). The ABOs included 143,000 early fetal deaths and stillbirths, 61,000 neonatal deaths, 41,000 preterm or low-birth weight births, and 109,000 infants with clinical CS. Of these ABOs- 203,000 (57%) occurred in pregnant women attending ANC but not screened for syphilis; 74,000 (21%) in mothers not enrolled in ANC, 55,000 (16%) in mothers screened but not treated, and 23,000 (6%) in mothers enrolled, screened and treated. The revised 2012 estimates were 0.70% (95% CI: 0.63-0.77%) maternal prevalence, and 748,000 CS cases (539 per 100,000 live births) including 397,000 (361,000-432,000) ABOs. The estimated decrease in CS case rates between 2012 and 2016 reflected increased access to ANC and to syphilis screening and treatment.
CONCLUSIONS
Congenital syphilis decreased worldwide between 2012 and 2016, although maternal prevalence was stable. Achieving global CS elimination, however, will require improving access to early syphilis screening and treatment in ANC, clinically monitoring all women diagnosed with syphilis and their infants, improving partner management, and reducing syphilis prevalence in the general population by expanding testing, treatment and partner referral beyond ANC.
Identifiants
pubmed: 30811406
doi: 10.1371/journal.pone.0211720
pii: PONE-D-18-26271
pmc: PMC6392238
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211720Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pediatr Rev. 1999 May;20(5):160-4, quiz 165
pubmed: 10233174
Sex Transm Dis. 2014 Feb;41(2):103-10
pubmed: 24413489
Bull World Health Organ. 2013 Mar 1;91(3):217-26
pubmed: 23476094
Lancet. 2016 Feb 6;387(10018):587-603
pubmed: 26794078
Lancet Glob Health. 2017 Oct;5(10):e977-e983
pubmed: 28911763
Sex Transm Dis. 2008 May;35(5):507-11
pubmed: 18356772
BMC Hematol. 2016 Nov 18;16:27
pubmed: 27891232
Saudi Med J. 2004 Dec;25(12):2037-8
pubmed: 15711700
J Infect Dev Ctries. 2015 Sep 27;9(9):1011-5
pubmed: 26409743
J Transl Med. 2012 Jan 31;10:20
pubmed: 22293125
Clin Infect Dis. 2018 Apr 3;66(8):1184-1191
pubmed: 29136161
PLoS One. 2014 Jul 15;9(7):e102203
pubmed: 25025232
Lancet Glob Health. 2016 Feb;4(2):e98-e108
pubmed: 26795602
PLoS One. 2013;8(2):e56713
pubmed: 23468875
Sci Rep. 2018 Jul 31;8(1):11503
pubmed: 30065272
PLoS One. 2013 Jun 26;8(6):e66905
pubmed: 23840552
Arch Iran Med. 2014 Sep;17(9):613-20
pubmed: 25204477
Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S10-4
pubmed: 25963909
PLoS One. 2014 Jan 29;9(1):e87510
pubmed: 24489931
Sex Transm Infect. 2017 Dec;93(8):599-606
pubmed: 28325771
BMC Public Health. 2011 Apr 13;11 Suppl 3:S9
pubmed: 21501460
Rev Panam Salud Publica. 2018 Sep 07;42:e118
pubmed: 31093146
PLoS Med. 2017 Dec 27;14(12):e1002473
pubmed: 29281619
Lancet Glob Health. 2016 Aug;4(8):e525-33
pubmed: 27443780
Sex Transm Dis. 2009 Nov;36(11):714-20
pubmed: 19773681
PLoS One. 2015 Jun 01;10(6):e0127728
pubmed: 26030741
PLoS Med. 2013;10(2):e1001396
pubmed: 23468598
J Infect Dev Ctries. 2013 Sep 16;7(9):665-9
pubmed: 24042102
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541